175 related articles for article (PubMed ID: 33358492)
1. Phase II trial of vaginal cuff brachytherapy followed by dose-dense chemotherapy in early stage endometrial cancer patients with enriched, high-intermediate risk factors for recurrence.
Castellano T; John Maxwell IV; Adam Walter J; Thompson S; McMeekin DS; Landrum LM
Gynecol Oncol; 2021 Mar; 160(3):669-673. PubMed ID: 33358492
[TBL] [Abstract][Full Text] [Related]
2. Phase II trial of vaginal cuff brachytherapy followed by chemotherapy in early stage endometrial cancer patients with high-intermediate risk factors.
Landrum LM; Nugent EK; Zuna RE; Syzek E; Mannel RS; Moore KN; Walker JL; McMeekin DS
Gynecol Oncol; 2014 Jan; 132(1):50-4. PubMed ID: 24219982
[TBL] [Abstract][Full Text] [Related]
3. Phase III Trial: Adjuvant Pelvic Radiation Therapy Versus Vaginal Brachytherapy Plus Paclitaxel/Carboplatin in High-Intermediate and High-Risk Early Stage Endometrial Cancer.
Randall ME; Filiaci V; McMeekin DS; von Gruenigen V; Huang H; Yashar CM; Mannel RS; Kim JW; Salani R; DiSilvestro PA; Burke JJ; Rutherford T; Spirtos NM; Terada K; Anderson PR; Brewster WR; Small W; Aghajanian CA; Miller DS
J Clin Oncol; 2019 Jul; 37(21):1810-1818. PubMed ID: 30995174
[TBL] [Abstract][Full Text] [Related]
4. Predictive factors of recurrence following adjuvant vaginal cuff brachytherapy alone for stage I endometrial cancer.
Dunn EF; Geye H; Platta CS; Gondi V; Rose S; Bradley KA; Anderson BM
Gynecol Oncol; 2014 Jun; 133(3):494-8. PubMed ID: 24657301
[TBL] [Abstract][Full Text] [Related]
5. A pilot trial of TAC (paclitaxel, doxorubicin, and carboplatin) chemotherapy with filgastrim (r-metHuG-CSF) support followed by radiotherapy in patients with "high-risk" endometrial cancer.
Duska LR; Berkowitz R; Matulonis U; Muto M; Goodman A; McIntyre JF; Klein A; Atkinson T; Seiden MV; Campos S
Gynecol Oncol; 2005 Jan; 96(1):198-203. PubMed ID: 15589601
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant carboplatin, paclitaxel, and vaginal cuff brachytherapy for stage III endometrial cancer: analysis of outcomes and patterns of recurrence based on pathologic characteristics.
Young MR; Higgins SA; Ratner E; Yu JB; Mani S; Silasi DA; Azodi M; Rutherford T; Schwartz PE; Damast S
Int J Gynecol Cancer; 2015 Mar; 25(3):431-9. PubMed ID: 25621409
[TBL] [Abstract][Full Text] [Related]
7. Vaginal high dose rate brachytherapy alone in patients with intermediate- to high-risk stage I endometrial carcinoma after radical surgery.
Atahan IL; Ozyar E; Yildiz F; Ozyigit G; Genc M; Ulger S; Usubutun A; Köse F; Yuce K; Ayhan A
Int J Gynecol Cancer; 2008; 18(6):1294-9. PubMed ID: 18284452
[TBL] [Abstract][Full Text] [Related]
8. Impact of different adjuvant radiotherapy modalities on women with early-stage intermediate- to high-risk endometrial cancer.
Jin M; Hou X; Sun X; Zhang Y; Hu K; Zhang F
Int J Gynecol Cancer; 2019 Oct; 29(8):1264-1270. PubMed ID: 31320487
[TBL] [Abstract][Full Text] [Related]
9. Vaginal cuff brachytherapy in the adjuvant setting for patients with high-risk early-stage cervical cancer.
Mauro GP; Kleine RT; da Costa SCS; Carvalho HA
Brachytherapy; 2019; 18(6):747-752. PubMed ID: 31607499
[TBL] [Abstract][Full Text] [Related]
10. Single-institutional outcomes of adjuvant brachytherapy for Stage I endometrial cancer-Are outcomes consistent with randomized studies?
Dohopolski MJ; Horne ZD; Gebhardt BJ; Glaser SM; Edwards RP; Kelley JL; Comerci JT; Olawaiye AB; Courtney-Brooks M; Berger JL; Sukumvanich P; Beriwal S
Brachytherapy; 2018; 17(3):564-570. PubMed ID: 29426745
[TBL] [Abstract][Full Text] [Related]
11. Outcomes and relapse patterns of stage IB grade 2 or 3 endometrial cancer treated with adjuvant vaginal brachytherapy.
Hochreiter A; Kelly JR; Young MR; Litkouhi B; Black JD; Stromberger C; Higgins S; Schwartz PE; Damast S
Int J Gynecol Cancer; 2020 Jan; 30(1):48-55. PubMed ID: 31722964
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant high dose rate vaginal brachytherapy as treatment of stage I and II endometrial carcinoma.
Horowitz NS; Peters WA; Smith MR; Drescher CW; Atwood M; Mate TP
Obstet Gynecol; 2002 Feb; 99(2):235-40. PubMed ID: 11814503
[TBL] [Abstract][Full Text] [Related]
13. Evaluating the relationship between vaginal apex "dog ears" and patterns of recurrence in endometrial cancer following adjuvant image guided vaginal cuff brachytherapy.
Venner EK; Ward KA; Wages NA; Walker B; Libby BP; Showalter TN; Romano KD
Brachytherapy; 2023; 22(2):139-145. PubMed ID: 36414525
[TBL] [Abstract][Full Text] [Related]
14. Do vaginal recurrence rates differ among adjuvant vaginal brachytherapy regimens in early-stage endometrial cancer?
Ager BJ; Francis SR; Do OA; Huang YJ; Soisson AP; Dodson MK; Werner TL; Sause WT; Grant JD; Gaffney DK
Brachytherapy; 2019; 18(4):453-461. PubMed ID: 31005603
[TBL] [Abstract][Full Text] [Related]
15. Preliminary analysis of RTOG 9708: Adjuvant postoperative radiotherapy combined with cisplatin/paclitaxel chemotherapy after surgery for patients with high-risk endometrial cancer.
Greven K; Winter K; Underhill K; Fontenesci J; Cooper J; Burke T;
Int J Radiat Oncol Biol Phys; 2004 May; 59(1):168-73. PubMed ID: 15093913
[TBL] [Abstract][Full Text] [Related]
16. Phase I clinical trial of weekly paclitaxel, weekly carboplatin, and concurrent radiotherapy for primary cervical cancer.
Rao GG; Rogers P; Drake RD; Nguyen P; Coleman RL
Gynecol Oncol; 2005 Jan; 96(1):168-72. PubMed ID: 15589596
[TBL] [Abstract][Full Text] [Related]
17. Intravaginal brachytherapy alone for intermediate-risk endometrial cancer.
Alektiar KM; Venkatraman E; Chi DS; Barakat RR
Int J Radiat Oncol Biol Phys; 2005 May; 62(1):111-7. PubMed ID: 15850910
[TBL] [Abstract][Full Text] [Related]
18. High-dose-rate postoperative vaginal cuff irradiation alone for stage IB and IC endometrial cancer.
Anderson JM; Stea B; Hallum AV; Rogoff E; Childers J
Int J Radiat Oncol Biol Phys; 2000 Jan; 46(2):417-25. PubMed ID: 10661349
[TBL] [Abstract][Full Text] [Related]
19. Feasibility study of combination chemotherapy with paclitaxel, doxorubicin and cisplatin without prophylactic granulocyte colony-stimulating factor injection for intermediate-to-high risk or recurrent endometrial cancer.
Nagao S; Nishikawa T; Hanaoka T; Kurosaki A; Iwasa N; Hasegawa K; Fujiwara K
Jpn J Clin Oncol; 2014 Nov; 44(11):1040-4. PubMed ID: 25183770
[TBL] [Abstract][Full Text] [Related]
20. Five-year outcomes of adjuvant carboplatin/paclitaxel chemotherapy and intravaginal radiation for stage I-II papillary serous endometrial cancer.
Kiess AP; Damast S; Makker V; Kollmeier MA; Gardner GJ; Aghajanian C; Abu-Rustum NR; Barakat RR; Alektiar KM
Gynecol Oncol; 2012 Nov; 127(2):321-5. PubMed ID: 22850412
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
